Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells

[1]  D. Jiao,et al.  MicroRNA-186 Suppresses Cell Proliferation and Metastasis Through Targeting Sentrin-Specific Protease 1 in Renal Cell Carcinoma. , 2018, Oncology research.

[2]  J. Vider,et al.  MicroRNA‐186‐5p overexpression modulates colon cancer growth by repressing the expression of the FAM134B tumour inhibitor , 2017, Experimental cell research.

[3]  Q. Ren,et al.  miRNA-186 inhibits prostate cancer cell proliferation and tumor growth by targeting YY1 and CDK6 , 2017, Experimental and therapeutic medicine.

[4]  Shun Xu,et al.  The Long Non-Coding RNA XIST Controls Non-Small Cell Lung Cancer Proliferation and Invasion by Modulating miR-186-5p , 2017, Cellular Physiology and Biochemistry.

[5]  Gerardo Botti,et al.  Micrornas in prostate cancer: an overview , 2017, Oncotarget.

[6]  K. D. Sørensen,et al.  miRNAs associated with prostate cancer risk and progression , 2017, BMC Urology.

[7]  Yue-ming Zhao,et al.  MiR-186 Inhibited Migration of NSCLC via Targeting cdc42 and Effecting EMT Process , 2017, Molecules and cells.

[8]  Hui Jiang,et al.  Dual Functional MicroRNA-186-5p Targets both FGF2 and RelA to Suppress Tumorigenesis of Glioblastoma Multiforme , 2017, Cellular and Molecular Neurobiology.

[9]  N. Leslie,et al.  Prostate cancer, PI3K, PTEN and prognosis. , 2017, Clinical science.

[10]  Y. Naya,et al.  The roles of microRNAs in the progression of castration-resistant prostate cancer , 2016, Journal of Human Genetics.

[11]  Stephen L. Abrams,et al.  Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer. , 2016, Biochimica et biophysica acta.

[12]  De-guang Sun,et al.  miR-186 affects the proliferation, invasion and migration of human gastric cancer by inhibition of Twist1 , 2016, Oncotarget.

[13]  Lei Sun,et al.  miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC). , 2016, Molecular bioSystems.

[14]  Yu Xiao,et al.  miR-186 inhibits cell proliferation of prostate cancer by targeting GOLPH3. , 2016, American journal of cancer research.

[15]  O. Olopade,et al.  Identification of a circulating MicroRNA signature to distinguish recurrence in breast cancer patients , 2016, OncoTarget.

[16]  S. Donnini,et al.  Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and −186 expression: Novel mechanism of VEGF modulation in prostate cancer , 2016, Oncotarget.

[17]  Qin Chen,et al.  miR186 suppresses prostate cancer progression by targeting Twist1 , 2016, Oncotarget.

[18]  Jun Yu,et al.  MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo signaling and tumorigenesis in hepatocellular carcinoma. , 2016, Oncology letters.

[19]  B. Kim,et al.  MicroRNA alteration and putative target genes in high‐grade prostatic intraepithelial neoplasia and prostate cancer: STAT3 and ZEB1 are upregulated during prostate carcinogenesis , 2016, The Prostate.

[20]  Guoqiang Zhao,et al.  microRNA-186 inhibits cell proliferation and induces apoptosis in human esophageal squamous cell carcinoma by targeting SKP2 , 2016, Laboratory Investigation.

[21]  W. Xia,et al.  MiR-103 regulates hepatocellular carcinoma growth by targeting AKAP12. , 2016, The international journal of biochemistry & cell biology.

[22]  H. Shen,et al.  miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin , 2016, Oncogene.

[23]  N. Gao,et al.  miR-186 inhibits cell proliferation in multiple myeloma by repressing Jagged1. , 2016, Biochemical and biophysical research communications.

[24]  Bin Wang,et al.  miR-186 downregulates protein phosphatase PPM1B in bladder cancer and mediates G1-S phase transition , 2016, Tumor Biology.

[25]  Y. Gan,et al.  MiR-186 suppresses the growth and metastasis of bladder cancer by targeting NSBP1 , 2015, Diagnostic Pathology.

[26]  R. Nolley,et al.  Elevated Serum MicroRNA Levels Associate with Absence of High-Grade Prostate Cancer in a Retrospective Cohort , 2015, PloS one.

[27]  Z. Bai,et al.  miR-186 and 326 Predict the Prognosis of Pancreatic Ductal Adenocarcinoma and Affect the Proliferation and Migration of Cancer Cells , 2015, PloS one.

[28]  H. Sültmann,et al.  Dependence of Intracellular and Exosomal microRNAs on Viral E6/E7 Oncogene Expression in HPV-positive Tumor Cells , 2015, PLoS pathogens.

[29]  P. P. Di Fiore,et al.  The role of non-coding RNAs in the regulation of stem cells and progenitors in the normal mammary gland and in breast tumors , 2015, Front. Genet..

[30]  O. Basturk,et al.  Epithelial and stromal expression of miRNAs during prostate cancer progression. , 2014, American journal of translational research.

[31]  Song Zhao,et al.  MiR-186 targets ROCK1 to suppress the growth and metastasis of NSCLC cells , 2014, Tumor Biology.

[32]  E. Nkenke,et al.  miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood. , 2014, Oncology reports.

[33]  Jianglin Zhang,et al.  Identification of differentially expressed microRNAs in metastatic melanoma using next-generation sequencing technology , 2014, International journal of molecular medicine.

[34]  M. Wirth,et al.  Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs , 2014, BMC Cancer.

[35]  Yonghong Sun,et al.  PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186. , 2013, Carcinogenesis.

[36]  Chenyu Zhang,et al.  Identification of four serum microRNAs from a genome-wide serum microRNA expression profile as potential non-invasive biomarkers for endometrioid endometrial cancer , 2013, Oncology letters.

[37]  Junchao Cai,et al.  miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. , 2013, Cancer research.

[38]  J. McCubrey,et al.  Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer. , 2013, Current medicinal chemistry.

[39]  Tian Wang,et al.  Screening of microRNA in patients with esophageal cancer at same tumor node metastasis stage with different prognoses. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[40]  J. Waxman,et al.  Wnt/β-catenin signalling in prostate cancer , 2012, Nature Reviews Urology.

[41]  I. Gelman.  Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12 , 2012, Cancer and Metastasis Reviews.

[42]  C. Plass,et al.  Down‐regulation of tumor suppressor a kinase anchor protein 12 in human hepatocarcinogenesis by epigenetic mechanisms , 2010, Hepatology.

[43]  Holger Sültmann,et al.  Serum microRNAs as non-invasive biomarkers for cancer , 2010, Molecular Cancer.

[44]  I. Gelman,et al.  Emerging Roles for SSeCKS/Gravin/AKAP12 in the Control of Cell Proliferation, Cancer Malignancy, and Barriergenesis. , 2010, Genes & cancer.

[45]  Lara J. Monteiro,et al.  Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. , 2009, Cancer research.

[46]  B. Su,et al.  SSeCKS/Gravin/AKAP12 Inhibits Cancer Cell Invasiveness and Chemotaxis by Suppressing a Protein Kinase C- Raf/MEK/ERK Pathway* , 2009, The Journal of Biological Chemistry.

[47]  Qizhi Yao,et al.  Profiling of 95 MicroRNAs in Pancreatic Cancer Cell Lines and Surgical Specimens by Real-Time PCR Analysis , 2009, World Journal of Surgery.

[48]  J. Potashkin,et al.  MicroRNAs miR-186 and miR-150 Down-regulate Expression of the Pro-apoptotic Purinergic P2X7 Receptor by Activation of Instability Sites at the 3′-Untranslated Region of the Gene That Decrease Steady-state Levels of the Transcript* , 2008, Journal of Biological Chemistry.

[49]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[50]  R. Stephens,et al.  Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. , 2008, Cancer research.

[51]  B. Foster,et al.  Loss of the SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasia. , 2008, Cancer research.

[52]  J. Davis.  Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .

[53]  I. Gelman,et al.  SSeCKS/Gravin/AKAP12 Metastasis Suppressor Inhibits Podosome Formation via RhoA- and Cdc42-Dependent Pathways , 2006, Molecular Cancer Research.

[54]  Claire L Weston,et al.  beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Rafael A. Irizarry,et al.  Bioinformatics and Computational Biology Solutions using R and Bioconductor , 2005 .

[56]  K. Pienta,et al.  The "emigration, migration, and immigration"of prostate cancer. , 2005, Clinical prostate cancer.

[57]  G. Saldanha,et al.  Nuclear β‐catenin in basal cell carcinoma correlates with increased proliferation , 2004, The British journal of dermatology.

[58]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[59]  Chen Liu,et al.  beta-Catenin is expressed aberrantly in tumors expressing shadow cells. Pilomatricoma, craniopharyngioma, and calcifying odontogenic cyst. , 2003, American journal of clinical pathology.

[60]  P. Unger,et al.  The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. , 2001, Cancer research.

[61]  R. Grosschedl,et al.  Regulation of LEF-1/TCF transcription factors by Wnt and other signals. , 1999, Current opinion in cell biology.

[62]  C. Kao,et al.  Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate‐specific antigen‐producing tumors in athymic and SCID/bg mice using LNCaP and lineage‐derived metastatic sublines , 1998, International journal of cancer.

[63]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.